



**FOR IMMEDIATE RELEASE:**

**BIO SUPPLY MANAGEMENT ALLIANCE LAUNCHES INDUSTRY RISK MANAGEMENT INITIATIVES**

**Steering Committee Consists of Leading Biotech Supply Chain Executives**

**San Francisco, California (August 17, 2010):** The Bio Supply Management Alliance (BSMA), representing a worldwide community of supply chain management professionals in the biotechnology industry, has launched an industry initiative to meet the challenges of risk management in the emerging global market. Based in the San Francisco Bay Area, home to more than 600 biotech firms, the BSMA has created a forum for collaboration, learning and best practice sharing of practitioners, executives and thought leaders.

"A very broad-based steering committee of industry executives has embarked upon addressing one of the most formidable challenges faced by the industry, namely management of risk in the end to end supply chain," says Devendra Mishra, the Executive Director of BSMA and adjunct professor of Pepperdine University's Graziadio School of Business & Management. "The leaders have demonstrated that achieving resilience in the supply chain while optimizing risks and rewards requires a collaborative effort amongst the stakeholders."

Chris Sam, chairman of the Risk Management Steering Committee observed, "We share a universal mission of supplying life-saving drugs to grievously ill patients. To do this, we strive to make supply as perfect and reliable as possible, in ensuring drugs and medical devices are safe, efficacious, secure, and delivered in a timely manner to patients. The patient-focused supply chain is perhaps more complex today than it has ever been, from raw materials that may be sourced on multiple continents, to global manufacturing that may be done in several stages around the world, to transporting these sensitive drugs through a complex, rapid distribution network of patient populations that are truly global."

"All of this happens seamlessly and relatively invisible to patients, as it should. Their focus has to remain on getting better," says Sam. "We do this by carefully evaluating and managing risks inherent in a complex supply chain, to ensure the weakest points in this chain are clearly identified and understood, with mitigation plans in place to ensure we can serve every patient, every time. This is an unyielding expectation of our patients, regulators, and investors. The Risk Management Steering Committee is made up of a truly talented group of professionals dedicated to continuously improving the industry's management of supply risk, to ensure we can keep this complexity in check by managing risk in supply, seamlessly and invisible to patients".

The Risk Management Steering Committee members are:



**Chris Sam, Chairman,** is the Executive Director of Craigshannock a Management Consulting firm providing enterprise, strategic and Operational Risk services. Prior to Craigshannock Chris led Amgen's Operations Risk Management organization since its inception in 2006. Chris's area of expertise is applying risk management to help shape a corporation's business strategy by protecting revenue, market share and shareholder value. The Operations Risk Management Team partners with business leaders and risk owners to understand and manage product supply risks to patients. Chris has worked in Risk Management for over 20 years, starting his career in the European oil and gas industry. He prepared and submitted to the UK regulatory agencies one of the first approved Offshore Safety Cases (or risk management plans) for oil and gas production facilities located in the European North Sea. In 1995, Chris was transferred to the US to the downstream refining and petrochemical business, with responsibility for developing risk management programs. He has also worked in the chemicals industry and established and ran a successful risk management consulting practice based in the US. Chris joined Amgen (from Exxon Mobil) to help establish a risk management program for the bio-pharma company. Chris is a member of the Executive Committee of the Strategic Risk Management Council of the Conference Board. His qualifications include a BSc with Honors and MSc in Risk Management from the Chemical Engineering Faculty of Sheffield University, England.



**Ron Bone** is the Senior Vice-President of Distribution Support at McKesson Pharmaceuticals. Ron has spent 38 years with McKesson Corp. in various operations, sales and financial management positions. His responsibilities include regulatory affairs and leading the company's product security initiatives through the use of electronic track-and-trace using RFID and Barcode technology. Mr. Bone is a member of the Leadership Teams of GS1 Global Healthcare and GS1 US Healthcare and a Member of the Industry Relations Council of HDMA. He received his Bachelor of Science and MBA degrees from San Jose State University.



**Arun Cavale** is a founding principal at NexInfo. He leads the Supply Chain and Manufacturing consulting practice. He along with his team have helped many Fortune 1000 clients including Beckman Coulter, Qualcomm, Pfizer, Hitachi, Sony, Toshiba and Kodak improve their supply chain delivery performance with successful planning initiatives. Arun provides thought leadership in the areas of Forecasting, Demand Management, Supply-Chain Planning and Risk Management. Starting off as a Production Planner his career spans over 22 years experience in manufacturing and supply-chain management. An active member of OAUG, APICS, IBF and other Supply Chain Organizations and is a recognized speaker on supply chain performance improvement issues.



**Fred Gvillo** blends strong business acumen with an appreciation of science and exceptional interpersonal skills, Fred is a master in the art of balancing science with the business of R&D. A voracious appetite for information keeps Fred informed about emerging issues that must be considered in biopharmaceutical strategies. He has worked in Global Research Administration for Schering AG; Business Development / Alliance Management with Codon; Supply Chain Management for Berlex Biosciences; New Market Development and product launch and Clinical Trial Manager for Genentech.



**Lewis T. Kontnik** is Director of Brand Protection for Amgen. Mr. Kontnik leads Amgen's Brand Protection program, a part of the company's Operations Risk Management function. In this role he developed and leads the company's functionally based global program responsible for fighting illegal counterfeiting, diversion and other brand attacks. This management system, made up of a set of durable, scalable business processes, protects the company's patients, products and brands. He also leads the company's serialization and pedigree regulatory requirements activities. Mr. Kontnik helps to lead the biopharma industry's anticounterfeiting activities including the PhRMA International Anticounterfeiting Committee (Chair), Supply Chain Security Work Group, BIO Anticounterfeiting Committee and the WHO IMPACT effort. Mr. Kontnik has been working to solve the global pharmaceutical counterfeiting problem for more than 15 years. He is a co-author of Counterfeiting Exposed (Wiley, 2003), Protecting Medicines: A Manual of AntiCounterfeiting Solutions (Reconnaissance, 2002). He served as a founder and chief technical consultant to the [www.SafeMedicines.org](http://www.SafeMedicines.org) partnership, consulted with the US Food and Drug Administration, World Health Organization and has spoken internationally on a various anti-counterfeiting topics. He is a member of the Washington, D.C. bar.



**Jane Lavine** has spent 20+ years in the insurance and risk management industry focusing on emerging life science companies. She has worked in Boston, San Diego and San Francisco heading up life science practices. She has worked with various companies, from start up through commercialization of products. As Client Executive for Life Science clients, she was responsible for consultative risk management analysis focusing on all types of risk a client may face, including: operational, financial, strategic and governance related issues. In her role, she was responsible for coordinating the delivery of all resources to the clients, supervising the client team, developing marketing strategies and developing solutions for a variety of business risks. She holds a Masters degree in Finance along with CPCU, ARM and CFE designations.



**Michael Mooney** is Director of Risk Management & Insurance – America’s for Expeditors, niche specialists in the supply chain risk management business helping customers build security, visibility and resilience into their existing supply chains. Throughout this time, Mr. Mooney has had a variety of responsibilities within the organization’s risk management and insurance division including claims service, subrogation management, contract negotiations, captive management, underwriting and overseeing the operations globally. Prior to joining Expeditors, Michael spent time in various areas of the financial services industry, including work with Merrill Lunch and First Union Securities. This Lake Tahoe, CA native played college baseball and is a graduate of Santa Clara University in finance. Michael also received his Associate in Risk Management Designation and is currently enrolled in the Executive MBA program through Seattle University.



**MS Sikka** is the founder and CEO of Sensitel, Inc. MS leads Sensitel's strategy and execution with the twin goals of reducing cost of product recalls and securing global supply chains. Prior to Sensitel, MS was Senior Director of Operations for NaturipeFarms, the largest Blueberry supplier in US. MS has held leadership positions at OpSec security, a provider of anti-counterfeiting solutions and i2 Technologies, a supply chain solutions company. Over his career, MS has brought multiple innovative solutions to market such as Prestigious Automotive News PACE Award winning vehicle sequencing solution, Mill scheduling solutions, RFID infrastructure software and Traceability Solutions for Food and Pharma industries. MS is also the founder of RFID Security Alliance. Mr. Sikka graduated as a Master of Manufacturing Engineering from Boston University and received his B.S. in Manufacturing Engineering from Indian Institute of Technology (IIT), Kharagpur. MS is an avid runner and recently ran the Marine Corps Marathon in Washington D.C.



**Tom Smith** is Director of Supply Chain / Materials Management for Shire Human Genetic Therapies where he is the corporate supply chain leader of Materials Planning and Purchasing, Supply Chain Systems, and Warehouse Operations. Tom leads the assessment and development of a Raw Materials Risk Mitigation program to address business risks introduced by single and sole source suppliers to Shire HGT’s Drug Substance supply chain. Tom is engaged in re-engineering the internal supply chain planning processes that drive the company’s internal manufacturing operations. Tom has held numerous Finance and Supply Chain leadership roles in both Biotech and Pharma industries at AstraZeneca, Wyeth. Tom holds an MBA from Babson College.



**Yingming Yue**, CPIM, is the Associate Director, Supplier Management with Nektar Therapeutics, a leading biopharmaceutical company with a robust pipeline of novel therapeutics. Prior to Nektar, He was an operations consultant with Deloitte Consulting and Pittiglio Rabin Todd & McGrath (PRTM). Yingming is a senior supply chain professional with 13 years experiences helping companies of various sizes improve operational efficiency and bottom line. He specialize in the areas of operational improvement, supply chain planning, material management, lean manufacturing, risk management, and global ERP implementation. His industry experience includes biotech, medical devices, semiconductor, computer, network equipment, and consumer electronics products. Mr. Yue received an MBA degree from The University of Chicago and MS in Applied Chemistry from Tianjin University. He also attended Operations Management Program from University of Texas at Austin. Yingming Yue is certified in Production and Inventory Management (CPIM) by APICS.

### **About the Bio Supply Management Alliance**

The Bio Supply Management Alliance was born of the need to create a worldwide community of operations and supply chain management leaders and professionals in the biotechnology industry. Based in the San Francisco Bay Area, home to more than 600 biotech firms, the Alliance provides a forum for collaboration, learning and best practice sharing of practitioners, executives and thought leaders in these uniquely demanding industry sectors. Founders **Tim Salaver** and **Devendra Mishra** have forged relationships with key industry leaders and defined initiatives with a vision to create process, people, and policy improvements in this vital sector. Our advisors are senior executives from top firms, thought leaders from academic institutions, such as MIT, UC Berkeley, Texas Christian University, Golden Gate University and Pepperdine University, and organizations such as APICS, the Association for Operations Management and Council for Supply Chain Management Professionals. Because life

depends on us<sup>TM</sup>, the Bio Supply Management Alliance supports B2B networking, continuous learning and career improvement of bio supply management professionals.

For more information, go to <http://www.biosupplyalliance.org>.

Contact:

Tim Salaver, Media Relations  
Bio Supply Management Alliance  
702-286-7464  
tim@biosupplyalliance.org  
<http://www.biosupplyalliance.org>

###

1,986 words